Hepion director Danina Fisher files Form 3

Hepion Pharmaceuticals, Inc. director Danina Fisher filed an initial Form 3, which is the required statement of beneficial ownership for insiders.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. director Danina Fisher filed an initial Form 3, which is the required statement of beneficial ownership for insiders. This filing lists Fisher as a director but shows no reported transactions or holdings data in the available summary fields.

Key Figures

Buy transactions reported: 0 Sell transactions reported: 0 Derivative transactions reported: 0

3 metrics

Buy transactions reported 0 Form 3 transaction summary buyCount

Sell transactions reported 0 Form 3 transaction summary sellCount

Derivative transactions reported 0 Form 3 transaction summary derivativeTransactionCount

Key Terms

Form 3, reporting insider, ten percent owner

3 terms

Form 3 regulatory

"Danina Fisher filed an initial Form 3, which is the required statement of beneficial ownership"

Form 3 is the initial public filing that officers, directors and large shareholders must submit to report their ownership of a company’s securities when they become insiders. It acts like an opening inventory sheet that gives investors a starting point to see who holds significant stakes and to spot later trades or potential conflicts of interest, helping assess insider confidence and transparency.

reporting insider regulatory

"The Form 3 establishes Danina Fisher as a reporting insider of Hepion Pharmaceuticals"

ten percent owner regulatory

"She is not listed as an officer and is not marked as a ten percent owner"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does Danina Fisher’s Form 3 mean for HEPA investors?

The Form 3 establishes Danina Fisher as a reporting insider of Hepion Pharmaceuticals. It is an initial ownership statement and, in this case, shows no reported transactions in the provided summary data.

Does the HEPA Form 3 for Danina Fisher show any stock transactions?

No, the Form 3 summary shows no buy, sell, or other transactions. All transaction-related counts, including buys, sells, exercises, gifts, and restructurings, are reported as zero in the transaction summary.

What insider role does Danina Fisher have at Hepion Pharmaceuticals (HEPA)?

Danina Fisher is identified as a director of Hepion Pharmaceuticals in the Form 3. She is not listed as an officer and is not marked as a ten percent owner in the provided data fields.

Does the Danina Fisher Form 3 for HEPA indicate any derivative positions?

No, the Form 3 shows an empty derivative summary. The derivativeSummary section contains no remaining options, warrants, or other derivatives based on the information provided.

Are there any footnote disclosures affecting Danina Fisher’s HEPA Form 3?

The footnotes field in the provided data is null, so there are no additional disclosures shown about voting power, investment authority, or related entities beyond the basic role information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Understanding Insider Trading Forms →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/08/2026 - 04:30 PM EDT Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Fisher Danina

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
07/01/2026

3. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Danina Fisher	07/08/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)